Investor Relations

General Information

Articles of Association

• Public Offering Information
• Articles of Association
• Capital Increase

Public Offering Documents:

• Explanation
• YKK and Report on Places of Use of the Fund

• Bonus Issue Capital Increase
• Paid Capital Increase

– 31.12.2021 – Consolidated Financial Statement Independent Auditor’s Report
– 30.09.2022 – Consolidated Financial Statement Independent Auditor’s Report
– 31.12.2022 – Consolidated Financial Statement Independent Auditor’s Report
– 31.03.2023 – Consolidated Financial Statement Independent Auditor’s Report
– 30.06.2023 – Consolidated Financial Statement Independent Auditor’s Report
– 30.09.2023 – Consolidated Financial Statement Independent Auditor’s Report
– 31.12.2023 – Consolidated Financial Statement Independent Auditor’s Report
– 30.09.2024 – Consolidated Financial Statement Independent Auditor’s Report

• Exception Disclosures

• Annual Reports

• Committees Duties and Working Principles
  – Working Principles of the Early Detection of Risk Committee
  – Working Principles of the Audit Committee
  – Working Principles of the Corporate Governance Committee

• 2019 Ordinary General Assembly Information
• 2020 Ordinary General Assembly Information
• 2021 Ordinary General Assembly Information
• Extraordinary General Assembly Information

• Donation & Aid Policy
• Profit Distribution Policy
• Pricing Policy
• Disclosure Policy

• Investor Presentation

• Improvement Action Plan for Timely Payment of Invoices

• Contact

Demirhan Erçıktı

Investor Relations Manager

Tel: 0312 219 50 33

Mail: yatirimciiliskileri@oncosem.com